Condition

Neurogenic Bladder

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 13 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials13
Recruiting1
Common interventions18
Lead sponsors shown10
Advertisement

Clinical trials

13 shown
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MSNCT06072703 · 2023-10-30
RECRUITING
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical StudyNCT05301335 · 2022-05-25
COMPLETED
Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple SclerosisNCT05587101 · 2021-10-19
UNKNOWN
Connected Catheter- Safety and Effectiveness StudyNCT03843073 · 2020-10-16
TERMINATED
Vaginal Estriol in Multiple SclerosisNCT03774407 · 2019-06-20
COMPLETED
PTNS on Urinary and Global Quality of Life in MS PatientsNCT04063852 · 2019-02-27
COMPLETED
Connected Catheter (C2P) Study for Bladder ManagementNCT03626324 · 2018-07-25
COMPLETED
Brain Targets in Patients With Bladder Emptying DifficultiesNCT03574610 · 2018-07-01
COMPLETED
Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)NCT02591901 · 2018-04-06
COMPLETED
Central Nervous System Changes Following OnabotulinumtoxinA Injection in the BladderNCT03033355 · 2014-02-01
COMPLETED
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)NCT01600716 · 2012-06-13
COMPLETED
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's DiseaseNCT01421719 · 2009-02-01
COMPLETED
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple SclerosisNCT00629642 · 2008-03-14
COMPLETED

Common interventions

Trial status mix

COMPLETED10
RECRUITING1
TERMINATED1
UNKNOWN1

Phase mix

NA5
PHASE22
PHASE32
PHASE42
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.